Amulirafusp alfa: Difference between revisions

Revision as of 06:09, 27 December 2024 editBoghog (talk \| contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,663 edits created drug stub		Revision as of 09:13, 27 December 2024 edit undoGraeme Bartlett (talk \| contribs)Administrators249,639 edits more idsNext edit →
Line 49:		Line 49:
	\| excretion =		\| excretion =
	<!-- Identifiers -->		<!-- Identifiers -->
	\| CAS_number =		\| CAS_number = 2850355-94-9
	\| PubChem =		\| PubChem =
	\| DrugBank =		\| DrugBank =
			\| UNII = HFR7WU5YK7
	\| KEGG =		\| KEGG =
	}}		}}

Revision as of 09:13, 27 December 2024

Pharmaceutical compound

Amulirafusp alfa (IMM0306) is a cancer immunotherapy that targets CD20-positive B-cell malignancies. It is a fusion protein that combines a CD20 monoclonal antibody with the CD47 binding domain of SIRPα, allowing it to simultaneously engage both CD20 and CD47 on cancer cells. Amulirafusp alfa has a dual mechanism of action that enhances both macrophage-mediated phagocytosis and natural killer cell activation.

Yang J, Song Y, Zhou K, Li Z, Zhang M, Jing H, Wang Z, Yu L, Meng W, Lu Q, Tian W, Shi Y (December 2024). "Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study". Journal of Hematology & Oncology. 17 (1): 123. doi:10.1186/s13045-024-01646-2. PMC 11657391. PMID 39696680.
Yang J, Li Z, Zhang M, Zhou K, Li Y, Yang Y, Wang Z, Yu L, Zhang J, Huang H, Cheng Y (September 2024). "839P Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma". Annals of Oncology. 35: S610. doi:10.1016/j.annonc.2024.08.890.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.